A Phase 3, Open Label 96-Week Extension Study of the Safety of Apricitabine in Treatment-Experienced HIV-1 Infected Patients Who Have Completed Protocol AVX-301 or AVX-302 or Who Have Met the Criteria for Open-Label Access to ATC [apricitabine] Because of Virological Failure/Lack of Response

Trial Profile

A Phase 3, Open Label 96-Week Extension Study of the Safety of Apricitabine in Treatment-Experienced HIV-1 Infected Patients Who Have Completed Protocol AVX-301 or AVX-302 or Who Have Met the Criteria for Open-Label Access to ATC [apricitabine] Because of Virological Failure/Lack of Response

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Apricitabine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Novita Healthcare
  • Most Recent Events

    • 28 Apr 2012 Planned number of patients changed from 1800 to 1866 as reported by European Clinical Trials Database.
    • 22 Jul 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top